Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Merck is making advances in the lucrative ulcerative colitis field with the key prize of its $11 billion buyout from several years ago.